Study of a new method to prepare stem cell transplants
Part of Immune system & allergy clinical trials.
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 0 and 30 years old when you are admitted for transplant
- You have a condition that doctors say requires a stem cell transplant (HCT)
- A donor has been found who is healthy and willing to donate bone marrow or stem cells
- The donor is not a fully matched brother/sister donor (except in Fanconi anemia)
- You (or your legal representative) can sign consent and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This study compares a newer type of stem cell transplant (using special cells) to the standard method for children who need a half-matched donor. It aims to see if the new approach is safer and works as well.
This trial tests a stem cell transplant that uses specially selected cells (CD34+ cells) to treat myelodysplastic syndrome (MDS), a blood disorder. The transplant comes from a donor and aims to replace unhealthy blood-forming cells with healthy ones, which may slow or stop the disease. It is designed for patients with higher-risk MDS or certain high-risk features.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Hear when a new Graft Vs Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.